It was reported that Pfizer has ended COVID-19 vaccine trial, with the success rate of 95% and two months of safety data. The drug maker said there were 170 cases of COVID-19 in its trial of more than 43,000 volunteers and only eight people with the disease had been given the shot rather than a placebo. It said that out of 10 people who developed severe COVID-19, one had received the vaccine. Pfizer also said on Wednesday that it would apply for an emergency U.S authorization within days and expected the U.S. Food and Drug Administration’s vaccine advisory committee to review and discuss the data in a public meeting that would hold in December. The drug company said that the vaccine side effects were mostly mild to moderate, the only severe effect of its two-dose vaccine, BNT162b2 that affected 3.7% of those vaccinated after the second dose was fatigue. It also stated that it would make as many as 50 million vaccine doses this year, which is expected to protect 25 million people, and in 2021, it would produce up to 1.3 billion doses.
Source: Viewers Corner News.